Bank of New York Mellon
MRNS

Bank of New York Mellon’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Bank of New York Mellon’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-160,161
Closed -$1.45M – 4323
2024
Q1 		$1.45M Sell
160,161
-9,391
-6% -$91.3K ﹤0.01% 2946
2023
Q4 		$1.84M Buy
169,552
+6,148
+4% +$46.1K ﹤0.01% 2874
2023
Q3 		$1.32M Sell
163,404
-366
-0.2% -$3.04K ﹤0.01% 3020
2023
Q2 		$1.78M Buy
163,770
+111,757
+215% +$957K ﹤0.01% 2908
2023
Q1 		$359K Buy
52,013
+32,896
+172% +$206K ﹤0.01% 3666
2022
Q4 		$76.1K Sell
19,117
-365
-2% -$1.79K ﹤0.01% 4170
2022
Q3 		$130K Sell
19,482
-780
-4% -$4.8K ﹤0.01% 4148
2022
Q2 		$98K Sell
20,262
-99,943
-83% -$608K ﹤0.01% 4226
2022
Q1 		$1.12M Sell
120,205
-331
-0.3% -$3.29K ﹤0.01% 3238
2021
Q4 		$1.43M Buy
120,536
+1,639
+1% +$18.9K ﹤0.01% 3179
2021
Q3 		$1.35M Buy
118,897
+16,270
+16% +$224K ﹤0.01% 3229
2021
Q2 		$1.84M Buy
102,627
+7,172
+8% +$115K ﹤0.01% 3035
2021
Q1 		$1.48M Buy
95,455
+7,158
+8% +$104K ﹤0.01% 3102
2020
Q4 		$1.08M Buy
88,297
+23,077
+35% +$322K ﹤0.01% 3218
2020
Q3 		$838K Buy
65,220
+3,534
+6% +$30.5K ﹤0.01% 3222
2020
Q2 		$627K Buy
61,686
+2,209
+4% +$20.3K ﹤0.01% 3364
2020
Q1 		$483K Buy
59,477
+26,879
+82% +$233K ﹤0.01% 3385
2019
Q4 		$282K Hold
32,598
– – ﹤0.01% 3828
2019
Q3 		$201K Sell
32,598
-1,667
-5% -$13.5K ﹤0.01% 3906
2019
Q2 		$569K Sell
34,265
-1,902
-5% -$33K ﹤0.01% 3535
2019
Q1 		$605K Buy
36,167
+9,844
+37% +$142K ﹤0.01% 3460
2018
Q4 		$302K Sell
26,323
-1,297
-5% -$26.2K ﹤0.01% 3708
2018
Q3 		$1.1M Buy
27,620
+980
+4% +$27.9K ﹤0.01% 3212
2018
Q2 		$754K Buy
26,640
+17,466
+190% +$387K ﹤0.01% 3402
2018
Q1 		$140K Buy
9,174
+872
+11% +$20.8K ﹤0.01% 3999
2017
Q4 		$271K Buy
8,302
+2,841
+52% +$76.6K ﹤0.01% 3841
2017
Q3 		$128K Buy
+5,461
New +$61.2K ﹤0.01% 3965
2017
Q2 		– Sell
-5,057
Closed -$36K – 4357
2017
Q1 		$36K Buy
+5,057
New +$27.2K ﹤0.01% 4178
2016
Q3 		– Sell
-4,119
Closed -$21K – 4324
2016
Q2 		$21K Sell
4,119
-15
-0.4% -$276 ﹤0.01% 4263
2016
Q1 		$89K Buy
+4,134
New +$87.6K ﹤0.01% 3982

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon's MRNS Position: Q2 2024 in Review

Bank of New York Mellon sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 160,161 shares — an estimated $1.45M sold.

Bank of New York Mellon first reported a position in MRNS in Q1 2016 and held it in 30 quarters. The position peaked at $1.84M in Q4 2023. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Bank of New York Mellon reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 160,161 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $1.45M.
  • Bank of New York Mellon first reported a position in Marinus Pharmaceuticals, Inc in Q1 2016 and held it in 30 quarters.
  • Bank of New York Mellon's Marinus Pharmaceuticals, Inc position peaked at $1.84M in Q4 2023.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.